Computational Modelling of TNFalpha Pathway in Parkinson's Disease (Sasidharakurup et al 2019)


Sasidharakurup H, Nair L, Bhaskar K, Diwakar S. (2019). Computational Modelling of TNFa Pathway in Parkinson’s Disease – A Systemic Perspective Complex Networks and Their Applications VIII. COMPLEX NETWORKS 2019. Studies in Computational Intell. 882

See more from authors: Sasidharakurup H · Nair L · Bhaskar K · Diwakar S

References and models cited by this paper

. (2015). Erratum: Borderud SP, Li Y, Burkhalter JE, Sheffer CE and Ostroff JS. Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer. doi: 10.1002/ cncr.28811. Cancer. 121 [PubMed]

Bezzi P et al. (2001). CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nature neuroscience. 4 [PubMed]

Clark IA. (2007). How TNF was recognized as a key mechanism of disease. Cytokine & growth factor reviews. 18 [PubMed]

Dufty BM et al. (2007). Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. The American journal of pathology. 170 [PubMed]

Fischer R, Maier O. (2015). Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxidative medicine and cellular longevity. 2015 [PubMed]

GBD 2016 Parkinson's Disease Collaborators. (2018). Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology. 17 [PubMed]

Hanisch UK. (2002). Microglia as a source and target of cytokines. Glia. 40 [PubMed]

Harms AS et al. (2011). Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Molecular therapy : the journal of the American Society of Gene Therapy. 19 [PubMed]

He J, Zhong W, Zhang M, Zhang R, Hu W. (2018). P38 Mitogen-activated Protein Kinase and Parkinson's Disease. Translational neuroscience. 9 [PubMed]

Hirsch EC. (2000). Glial cells and Parkinson's disease. Journal of neurology. 247 Suppl 2 [PubMed]

Inoue K. (2002). Microglial activation by purines and pyrimidines. Glia. 40 [PubMed]

Izumi Y et al. (2009). Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. Journal of neurochemistry. 110 [PubMed]

Ji Z, Yan K, Li W, Hu H, Zhu X. (2017). Mathematical and Computational Modeling in Complex Biological Systems. BioMed research international. 2017 [PubMed]

Junn E, Mouradian MM. (2001). Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. Journal of neurochemistry. 78 [PubMed]

Kouchaki E et al. (2018). Increased serum levels of TNF-a and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clinical neurology and neurosurgery. 166 [PubMed]

Leal MC, Casabona JC, Puntel M, Pitossi FJ. (2013). Interleukin-1ß and tumor necrosis factor-a: reliable targets for protective therapies in Parkinson's Disease? Frontiers in cellular neuroscience. 7 [PubMed]

Lindenau JD, Altmann V, Schumacher-Schuh AF, Rieder CR, Hutz MH. (2017). Tumor necrosis factor alpha polymorphisms are associated with Parkinson's disease age at onset. Neuroscience letters. 658 [PubMed]

Nagatsu T, Sawada M. (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. Journal of neural transmission. Supplementum. [PubMed]

Negro S et al. (2016). ATP Released by Injured Neurons Activates Schwann Cells. Frontiers in cellular neuroscience. 10 [PubMed]

Olmos G, Lladó J. (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators of inflammation. 2014 [PubMed]

Parent A, Parent M, Charara A. (1999). Glutamatergic inputs to midbrain dopaminergic neurons in primates. Parkinsonism & related disorders. 5 [PubMed]

Perez RG et al. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22 [PubMed]

Peter I et al. (2018). Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA neurology. 75 [PubMed]

Qian L, Flood PM. (2008). Microglial cells and Parkinson's disease. Immunologic research. 41 [PubMed]

Ragothaman M, Govindappa ST, Rattihalli R, Subbakrishna DK, Muthane UB. (2006). Direct costs of managing Parkinson's disease in India: concerns in a developing country. Movement disorders : official journal of the Movement Disorder Society. 21 [PubMed]

Sasidharakurup H, Melethadathil N, Nair B, Diwakar S. (2017). A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. Omics : a journal of integrative biology. 21 [PubMed]

Smith PD et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 100 [PubMed]

Stayte S, Vissel B. (2014). Advances in non-dopaminergic treatments for Parkinson's disease. Frontiers in neuroscience. 8 [PubMed]

Takeuchi H et al. (2006). Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. The Journal of biological chemistry. 281 [PubMed]

Vincent VA, Tilders FJ, Van Dam AM. (1997). Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta. Glia. 19 [PubMed]

Welser-Alves JV, Milner R. (2013). Microglia are the major source of TNF-a and TGF-ß1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochemistry international. 63 [PubMed]

Wood LB, Winslow AR, Strasser SD. (2015). Systems biology of neurodegenerative diseases. Integrative biology : quantitative biosciences from nano to macro. 7 [PubMed]

References and models that cite this paper
This website requires cookies and limited processing of your personal data in order to function. By continuing to browse or otherwise use this site, you are agreeing to this use. See our Privacy policy and how to cite and terms of use.